Gilead’s long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales
31st October 2025 Uncategorised 0Gilead’s long-acting pre-exposure prophylaxis med Yeztugo has garnered $54 million in sales since its June launch in the U.S., the company reported, bolstering its HIV franchise as cell therapy sales continue to decline.
More: Gilead’s long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales
Source: fierce